Please login to the form below

Not currently logged in
Email:
Password:

trebananib

This page shows the latest trebananib news and features for those working in and with pharma, biotech and healthcare.

Takeda hands back rights to two Amgen drugs

Takeda hands back rights to two Amgen drugs

However, Takeda has decided it is no longer interested in developing pain candidate fulranumab (AMG403) and trebananib (AMG386), which is being tested in cancer. ... In the case of trebananib the picture seems clearer - the compound has already failed

Latest news

  • Amgen's trebananib misses survival target in ovarian cancer Amgen's trebananib misses survival target in ovarian cancer

    tumours. In the phase III study - called TRINOVA-1 - trebananib plus paclitaxel was compared to paclitaxel alone in women with recurrent platinum-resistant ovarian cancer. ... he described the overall survival data from TRINOVA-1 as a "binary event" for

  • Late-stage ovarian cancer Late-stage ovarian cancer

    Trebananib appears to be closer than nintedanib to approval, given that the primary endpoint (PFS) was achieved in the phase III TRINOVA-1 trial. ... In this trial, 919 patients with recurrent ovarian, primary peritoneal or fallopian tube cancers were

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....